10x Genomics
TXG
314 hedge funds and large institutions have $6.29B invested in 10x Genomics in 2022 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 135 increasing their positions, 72 reducing their positions, and 96 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 135 | Existing positions reduced: 72
1.43% more ownership
Funds ownership: 87.32% → 88.75% (+1.4%)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
14% less funds holding
Funds holding: 365 → 314 (-51)
35% less call options, than puts
Call options by funds: $20.5M | Put options by funds: $31.7M
47% less capital invested
Capital invested by funds: $11.9B → $6.29B (-$5.58B)
48% less first-time investments, than exits
New positions opened: 50 | Existing positions closed: 96
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$389M |
| 2 |
Sands Capital Management
Arlington,
Virginia
|
+$134M |
| 3 |
BlackRock
New York
|
+$99.6M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$63.9M |
| 5 |
1WCM
12 West Capital Management
New York
|
+$45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$268M |
| 2 |
DCP
D1 Capital Partners
New York
|
-$239M |
| 3 |
William Blair Investment Management
Chicago,
Illinois
|
-$159M |
| 4 |
JCM
JS Capital Management
New York
|
-$80.5M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$68.3M |
TXG Hedge Fund Activity: Q1 2022 in Review
314 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q1 2022, worth a combined $6.29B — down 47% from $11.9B a quarter earlier.
Sellers outnumbered buyers: 96 funds closed out of TXG and 50 opened new positions — a net loss of 46 holders — while 72 trimmed existing stakes and 135 added.
The largest buyer was Morgan Stanley, adding an estimated $389M. The largest seller was Fidelity Investments, cutting an estimated $268M.
- 314 institutional investors held 10x Genomics (TXG) as of Q1 2022, down from 365 in Q4 2021.
- Funds reported $6.29B of 10x Genomics stock for Q1 2022, down 47% quarter-over-quarter.
- 50 funds opened new 10x Genomics positions in Q1 2022 and 96 closed out, a net change of -46 holders.
- The largest 10x Genomics buyer in Q1 2022 was Morgan Stanley, an estimated $389M added.
- The largest 10x Genomics seller in Q1 2022 was Fidelity Investments, an estimated $268M sold.
Based on aggregated 13F filings for Q1 2022.